{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:28:59Z","timestamp":1791563339385,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jchf.2019.05.009","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T16:09:37Z","timestamp":1568218177000},"page":"823-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Diagnostic and Therapeutic Gaps in\u00a0Patients With Heart\u00a0Failure and Chronic\u00a0Obstructive Pulmonary\u00a0Disease"],"prefix":"10.1016","volume":"7","author":[{"given":"Marco","family":"Canepa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits M.E.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Olschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2019.05.009_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000448166","article-title":"Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI-HF trial","volume":"136","author":"Canepa","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.jchf.2019.05.009_bib2","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1093\/eurheartj\/eht192","article-title":"Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services","volume":"34","author":"Hawkins","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.05.009_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ejhf.964","article-title":"Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart\u00a0Failure Long-Term Registry","volume":"20","author":"Canepa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.05.009_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.05.009_bib6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","article-title":"Beta-blockers are associated with a reduction in COPD exacerbations","volume":"71","author":"Bhatt","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jchf.2019.05.009_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary","volume":"195","author":"Vogelmeier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ejhf.986","article-title":"Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care","volume":"20","author":"Hawkins","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ejhf.946","article-title":"What can we learn from pulmonary function testing in heart failure?","volume":"19","author":"Magnussen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/thx.2006.068379","article-title":"Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?","volume":"62","author":"Mannino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jchf.2019.05.009_bib12","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2019.05.009_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A\u00a0summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2019.05.009_bib14","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib15","first-page":"CD003566","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease","volume":"4","author":"Salpeter","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jchf.2019.05.009_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113048","article-title":"Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies","volume":"9","author":"Du","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jchf.2019.05.009_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart\u00a0Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1378\/chest.14-0607","article-title":"Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart\u00a0Failure Study","volume":"147","author":"Fisher","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2019.05.009_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/eurjhf\/hfs009","article-title":"Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF","volume":"14","author":"Mentz","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ejhf.1202","article-title":"Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study","volume":"20","author":"Iorio","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ejhf.1073","article-title":"Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib23","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","article-title":"Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists","volume":"57","author":"Hawkins","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib24","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","article-title":"Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial","volume":"55","author":"Jabbour","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ejhf.1045","article-title":"Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study","volume":"20","author":"Sessa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.amjcard.2012.10.041","article-title":"Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF)","volume":"111","author":"Mentz","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjcard.2015.01.545","article-title":"Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure","volume":"115","author":"Briasoulis","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jchf.2019.05.009_bib29","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/eurheartj\/eht279","article-title":"Should we revise our approach to \u201coptimal medical therapy\u201d? The case of chronic heart failure","volume":"34","author":"Tavazzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.05.009_bib30","first-page":"109","article-title":"Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial","volume":"4","author":"Fiuzat","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2019.05.009_bib31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2013.10.068","article-title":"Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study","volume":"170","author":"Tavazzi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2019.05.009_bib33","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2019.05.009_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2019.05.009_bib35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2019.05.009_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib39","doi-asserted-by":"crossref","first-page":"1602245","DOI":"10.1183\/13993003.02245-2016","article-title":"Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events","volume":"49","author":"Suissa","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jchf.2019.05.009_bib40","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1378\/chest.123.6.1964","article-title":"Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction","volume":"123","author":"Au","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jchf.2019.05.009_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/eurjhf\/hfr063","article-title":"Are beta2-agonists responsible for increased mortality in heart failure?","volume":"13","author":"Bermingham","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.471","article-title":"The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database","volume":"18","author":"Maggioni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib43","first-page":"647","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2019.05.009_bib44","first-page":"654","article-title":"Beta-blockers in acute heart failure: do they cause harm?","volume":"3","author":"Jondeau","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2019.05.009_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/thoraxjnl-2012-201945","article-title":"Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension","volume":"67","author":"Stefan","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jchf.2019.05.009_bib46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.05.009_bib47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1164\/rccm.201801-0095PP","article-title":"Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype?","volume":"198","author":"Kovacs","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib48","doi-asserted-by":"crossref","first-page":"e003703","DOI":"10.1161\/CIRCHEARTFAILURE.116.003703","article-title":"Use of \u03b2-blockers in pulmonary hypertension","volume":"10","author":"Perros","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2019.05.009_bib49","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.amjmed.2004.07.043","article-title":"Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease","volume":"117","author":"Au","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib50","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2019.05.009_bib51","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","article-title":"Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease","volume":"170","author":"Rutten","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2019.05.009_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ehf2.12228","article-title":"Chronic obstructive pulmonary disease and beta-blocker treatment in Asian patients with heart failure","volume":"5","author":"Kubota","year":"2018","journal-title":"ESC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919304019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919304019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:52:14Z","timestamp":1761972734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177919304019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2213177919304019"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2019.05.009","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and Therapeutic Gaps in\u00a0Patients With Heart\u00a0Failure and Chronic\u00a0Obstructive Pulmonary\u00a0Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2019.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}